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Background: The role of human papillomavirus (HPV) in the development of esophageal cancer remains
controversial. Our study aims to test the association between HPV 16 infection and esophageal cancer in China,
providing useful information on this unclear association in Chinese population.
Methods: Studies on HPV infection and esophageal cancer were identified. A random-effects model was used to
calculate the odds ratios (ORs) and corresponding 95% confidence intervals (CIs) comparing cases with controls.
Results: A total of 1442 esophageal cancer cases and 1602 controls from 10 included studies were evaluated to
estimate the association between HPV 16 infection and esophageal cancer risk. The ORs for each case–control
studies ranged from 3.65 (95% CI: 2.17, 6.13) to 15.44 (95% CI: 3.42, 69.70). The pooled estimates for OR was 6.36
(95% CI: 4.46, 9.07). In sensitivity analysis, the estimates for OR ranged from 5.92 (95% CI: 4.08, 8.60) to 6.97 (95% CI:
4.89, 9.93).
Conclusions: This study indicates that HPV-16 infection may be a risk factor for esophageal cancer among Chinese
population, supporting an etiological role of HPV16 in this malignancy. Results in this study may have important
implications for esophageal cancer prevention and treatment in China.
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Esophageal cancer is the eighth most common malig-
nancy worldwide and a majority of cases show poor prog-
nosis in clinical practice [1]. Based on IARC statistics,
there are 456,000 new cases (3.2% of the total) and
400,000 deaths (4.9% of the total) in 2012 [1]. Globally,
around 80% of the cases worldwide occur in less devel-
oped regions. China has a high burden of esophageal can-
cer. The incidence and mortality of esophageal cancer in
China were 22.4/100000 and 16.77/100000 [2], respect-
ively. It is becoming a substantial medical and public
health challenge in China.
In the past few decades, many risk factors for esopha-
geal cancer have been investigated, including tobacco* Correspondence: xbsun21@sina.com
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unless otherwise stated.smoking, alcohol drinking, dietary and micronutrient
deficiency, high temperature of beverage and food con-
sumption, poverty and history of head and neck cancer
[3]. However, the etiology of esophageal cancer is still
unclear. In China, infectious agents contributed more
than one quarter of the overall cancer cases [4]. The role
of infectious agents in esophageal carcinogenesis has
also been suggested as either direct carcinogens or
promoters.
Human papillomavirus (HPV) has been suggested as a
distinct possible cause of esophageal cancer. To date,
more than 140 HPV genotypes have been recognized
and subdivided into cutaneous and mucosal HPV types.
Based on the oncogenicity, HPV are classified into high-
risk and low-risk types. High-risk HPV 16 infection is
more prevalent than any other high-risk HPV type in
most regions of the world [5]. As the upper gastrointes-
tinal tract might be exposed to HPV through oralThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tributor to esophageal cancer was hypothesised over
three decades ago [6].
The role of HPV in the development of esophageal
cancer remains controversial. The prevalence of HPV
infection in esophageal lesion or carcinomas varied
largely in different studies [7]. Syrjanen et al. summa-
rized the HPV prevalence of any type in esophageal
cancer and reported that the mean prevalence of HPV
was 29.0%, ranging from 0% to 78% [8]. Some studies
reported that the prevalence of HPV were relatively high
in high risk areas of esophageal cancer in the world [9].
Studies also showed a positive correlation between HPV
16 and esophageal cancer [10-12]. However, the associ-
ation between HPV 16 infection and esophageal cancer
in Chinese population has not yet been assessed clearly.
Establishing the relationship between HPV 16 infection
and esophageal cancer may improve our understanding
of its role and give some clues of immune efficacy of
HPV vaccine for esophageal cancer, which have been
successfully applied on cervical cancer. Therefore, we
conducted this study to assess the association between
HPV 16 infection and risk of esophageal cancer in
China, providing useful information on this unclear
association in Chinese population.
Methods
Literature search
A systematic search was conducted to identify relevant
articles, using MEDLINE (via PubMed), Excerpta Medica
database (EMBASE) for English language, and using
Chinese National Knowledge Infrastructure and Wanfang
Data Knowledge Service Platform for Chinese language.
Date of the literature was specified between 1 Jan 2005
and 1 July 2014. The search strategy was verified by a
medical reference librarian and research articles were
selected using the following keywords: human papilloma-
virus, papillomavirus infections, (o) esophageal neoplasms,
(o) esophageal cancer, and (o) esophageal carcinoma. The
search strategy was adapted for each database in order to
maximize the ability to identify eligible studies. Reference
lists of the included studies and published meta-analyses
on related topics were also screened for additional studies.
Eligible criteria
Two authors independently reviewed the identified rele-
vant articles and judged whether they met the inclusion
criteria for meta-analysis. Uncertainties and discrepan-
cies were resolved by consensus after discussion with a
senior author. The meta-analysis included studies in
adults meeting the following criteria: (1) case–control
studies or cohort studies; (2) studies detected HPV DNA
in the tissues of subjects; (3) samples of control
group must be taken from normal population withoutesophageal cancer; (4) studies explicitly provided the
information on HPV DNA detection method. HPV
DNA must be tested either by polymerase chain reac-
tion (PCR)-based methods, including broad-spectrum
PCR primers, type-specific PCR primers, or a combin-
ation of both kinds of primers; (5) necessary data
could be directly extracted or calculated from the ori-
ginal article; (6) studies were peer-reviewed publica-
tions with HPV prevalence data from a minimum of
30 cases of esophageal cancer; and (7) studies con-
ducted in the Chinese population. If the study was
reported in duplication, the one published earlier or
provided more detailed information was included. Re-
view articles and editorials were included if they con-
tained original data. Abstracts were excluded.
Data extraction
Two authors performed the data extraction from each
article and discrepancies were resolved by consensus.
For studies meeting the inclusion criteria, a standard
data extraction form was used to extract the following
data: general information, including name of first author,
year of publication, geographical areas of the study
origin; numbers of cases/controls and HPV positive
cases/controls; HPV detection method; and types of spe-
cimen (paraffin-embedded fixed biopsies (PE), fresh or
frozen biopsies (FF)).
Statistical analyses
In this meta-analysis, the association between HPV
infection and cancer risk was estimated by means of
odds ratios (ORs) and corresponding 95% confidence
intervals (CIs) comparing cases with controls through
the method of DerSimonian and Laird using the as-
sumptions of a random-effects model [13]. For subjects
with multiple HPV types infection (including HPV 16),
the multiple HPV types were separated into different
types and the HPV 16 type-specific prevalence repre-
sents types for subjects with either single HPV 16 infec-
tion or multiple HPV 16 infection. When multiple
control groups were studied, we selected the group of
subjects providing normal mucosal biopsies.
Heterogeneity between eligible studies were assess by
I2 (values of 25%, 50% and 75% corresponding to low,
moderate and high degrees of heterogeneity, respect-
ively) and Cochrane Q test (P < 0.10 indicated a high
level of statistical heterogeneity) [14]. Stratified pooled
analyses were subsequently carried out according to the
geographical areas of the study origin, publication years,
HPV detection method and types of specimen. Sensitiv-
ity analysis was conducted to assess the influence of each
individual study on the strength and stability of the
meta-analytic results. Each time, one study in the meta-
analysis was excluded to see its impact on the combined
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Egger’s tests and also by examining for irregularities in
funnel plots demonstrating the relationship between the
individual log ORs and their standard errors [15,16]. In
addition, a cumulative meta-analysis was conducted to
investigate the cumulative evidence at the time that each
study was published to show the trend of results over
time.
In this study, meta-analyses were performed using
STATA version 12 for Windows (StataCorp LP, College
Station, TX, USA). A two-tailed P < 0.05 was considered
statistically significant.Results
Figure 1 shows the flow diagram for the selection of
included studies. The systematic literatures search
yielded 417 articles relevant to the topic using differ-
ent combination of key words, of which 156 were con-
sidered as having potential value and the full texts
were retrieved for detailed evaluation. One hundred
and twenty-two of the 156 articles were subsequently
excluded from the meta-analysis. The majority of the
reasons for exclusion were: studies not conducted in
Chinese population, studies not related to HPV 16 or
studies not tested by PCR-based assay. Duplicated studies
and reviews without detailed information were also
excluded. Furthermore, twenty-four studies were also
excluded as they were not case control or cohort studies.Figure 1 Flow diagram for the selection of included studies.At last, we included 10 eligible studies in the meta-
analysis [17-26].
Individual characteristics of the included 10 studies
were summarized in Table 1. The included studies were
conducted during 2007–2014. In total, 1442 esophageal
cancer cases and 1602 controls were evaluated to esti-
mate the association between HPV 16 infection and
esophageal cancer risk in the 10 included studies. Of
these studies, 3 were conducted in Henan province, and
other studies were conducted in provinces of Xinjiang
(3), Shandong (1), Shaanxi (1), Chongqing (1) and
Guangdong (1). The most used types of esophageal spec-
imens to test HPV DNA status were PE, which
accounted for 70% of the included studies, and the other
30% specimens were FF. The HPV detection region of
these studies were L1 (50%) or HPV E6 (50%). In the
eligible studies, the HPV 16 prevalence ranged from
0.23 to 0.69 in cases. With respect to controls, the
HPV 16 prevalence was mainly from 0.02 to 0.22,
except one study in which the prevalence was 0.37,
much higher than other studies.
Based on the heterogeneity test, there was a mod-
erate heterogeneity between included studies (Q test
Pheterogeneity < 0.001, I
2 = 55.1%). Therefore, the random-
effects model was chosen to evaluate the pooled ORs.
Individual and pooled OR estimates derived from a
random effect model analysis were illustrated in the
Forest plot. As shown in Figure 2, the ORs for each
case–control studies ranged from 3.65 (95% CI: 2.17,
Table 1 Characteristics of 10 studies included in the meta-analysis












Liu et al. [17] Chongqing 43/112 0.38 4/74 0.05 FF L1
He et al. [18] Henan 56/110 0.51 7/45 0.16 FE E6
Chen et al. [19] Xinjiang 34/80 0.43 11/80 0.14 FE E6
Liu et al. [20] Shaanxi 35/69 0.51 2/32 0.06 FE E6
Han and Chen [21] Shandong 121/204 0.59 12/102 0.12 FE L1
Guo et al. [22] Henan 70/300 0.23 21/900 0.02 FF L1
Hu et al. [23] Xinjiang 82/200 0.41 24/150 0.16 FE E6
Liu et al. [24] Henan 54/78 0.69 11/30 0.37 FF L1
Zhang et al. [38] Guangdong 62/106 0.58 22/100 0.22 FE E6
Cui et al. [26] Xinjiang 53/183 0.29 8/89 0.09 FE L1
1FF: Fresh-Frozen; PE: Paraffin-Embedded.
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mates for OR was 6.36 (95% CI: 4.46, 9.07), indicating
a significant association between HPV 16 infection
and esophageal cancer.
Results stratified by geographical areas of the study
origin, publication years, types of specimen and HPV
detection method were presented in Table 2. Based on
these information, we can observed that the point esti-
mate for pooled OR was higher for studies conducted in
Northern China. Similarly, studies which HPV DNA
extracted from FF tissues, or which detected gene from
L1 region of HPV were generally revealed to be higher
point estimate.
Figure 3 showed the results of cumulative random-
effects meta-analysis of the 10 studies. All studies revealed
a positive association between HPV 16 and esophagealFigure 2 Forest plot for meta-analysis of the association of HPV withcancer. There was a weaker association in the earliest
study conducted in 2007 (OR = 5.63, 95% CI: 2.32, 13.69),
compared to the latest study in 2014 with a cumulative
estimate of 6.36 (95% CI: 4.46, 9.07). The confidence
interval for the summary estimate of the cumulative stud-
ies decreased with time of studies (Figure 3).
To address the potential bias due to the quality of the
included studies, we performed the sensitivity analysis
by calculating pooled OR again when omitting one study
each time. Figure 4 showed the results of sensitivity ana-
lysis. The estimates for OR ranged from 5.92 (95% CI:
4.08, 8.60) to 6.97 (95% CI: 4.89, 9.93). Results did not
show significant differences when any study was omit-
ted, which indicated that each single study did not influ-
ence the stability of the association between HPV 16 and
esophageal cancer.esophageal cancer in 10 case–control studies.
Table 2 Meta-analysis of the association between HPV 16 and esophageal cancer by different variables
Variable Number of studies OR (95% CI) Heterogeneity
P for Q test I2 (%)
Region
North 4 8.15 (4.79, 13.86) 0.084 54.9
Northwest 4 4.36 (2.95, 6.44) 0.357 7.2
South 2 6.50 (3.12, 13.55) 0.209 36.5
Year
2005-2009 4 6.65 (4.07, 10.86) 0.384 1.60
2010-2014 6 6.03 (3.72, 9.77) 0.004 70.7
Specimen(1)
PE 7 5.48 (3.88, 7.52) 0.169 34.0
FF 3 8.48 (3.99, 9.41) 0.072 61.9
HPV detection method
L1 5 7.87 (4.71, 13.16) 0.052 57.3
E6 5 4.68 (3.40, 6.44 ) 0.473 0.00
(1)FF: Fresh-Frozen; PE: Paraffin-Embedded.
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(Not shown). According to Begg’s and Egger’s test, there
was no evidence of publication bias (Begg P = 0.721,
Egger P = 0.878).Discussion
To our knowledge, this is the first meta-analysis that
aimed to explore the association between HPV 16 and
esophageal cancer in Chinese population, including 1442
esophageal cancer cases and 1602 controls. This meta-
analysis highlights an over sixfold increased risk of
esophageal cancer in the presence of HPV 16 infection,
providing a strong evidence to date of a potential roleFigure 3 Cumulative meta-analysis of case control studies for the evifor HPV 16 in the etiology of esophageal cancer in Chin-
ese population.
Results in our meta-analysis are consistent with other
studies. Yong et al. reported an OR of 3.55 (95% CI:
2.05, 6.14) between HPV 16 infection and esophageal
cancer. Li et al. reported a similar OR of 3.52 (95% CI,
2.04–6.07) [11]. Hardefeldt et al. also investigated this
issue and acquired an OR of 2 · 35 (95% CI: 1.73, 3.19)
[12]. Although all these studies showed an increased risk
associated with HPV 16 infection, the pooled OR (6.36,
95% CI: 4.46, 9.07) in our meta-analysis is relatively
higher than other studies. This is not surprising if we
consider the inclusion criteria of this meta-analysis. We
only included studies provided the information of HPVdence of association between HPV and esophageal cancer.
Figure 4 Sensitivity analysis for individual studies on the summary effect.
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than other methods, such as in situ hybridization histo-
chemistry. Even more importantly, samples of control
group were taken from normal population without
esophageal cancer. Studies using other normal partici-
pants had a higher risk than studies with adjacent nor-
mal mucosa as the normal control [27]. This was
possibly due to paraneoplastic impairment of the local
oesophageal mucosal immunity and using adjacent nor-
mal mucosa as controls could not exclude this effect.
Therefore, independent normal controls should yield a
more accurate estimate of the risk.
Some factors might contribute to the variability of
results on evaluating the association of HPV 16 infection
and esophageal cancer. In our study, stratified analyses
were performed according to geographical areas of the
study origin, publication years, HPV detection method
and types of specimen. Based on the results, we found
that samples from FF tissues had a higher point estimate
of OR than samples from PE tissues. This is mainly due
to the DNA degradation in PE tissue [28]. We also
found that the DNA source of HPV can also affect the
estimate of risk. In the future study investigating the
relationship between type specific HPV and esophageal
cancer, these factors should be considered to acquire a
more realistic result.
Our results may have important implications for
esophageal cancer prevention and treatment. To date,
two vaccines have been developed and approved for use
against HPV. Gardasil is a quadrivalent vaccine that tar-
gets HPV-6, −11, −16, and −18. The bivalent vaccine
Cervarix targets HPV-16 and −18. Recently, the success
of the prophylactic immunization campaign for cervical
cancer has attracted a lot of interest in preventable HPVrelated cancers, including esophageal cancer. However,
the association between HPV and esophageal cancer is
controversial since it was first reported by Syrjänen [29].
Therefore, an established association between type-
specific HPV infection and esophageal cancer is essential
for HPV screening and vaccination policies. Results in
our study support that HPV vaccine could benefit popu-
lations at high risk of esophageal cancer in China, which
is a good sign for alleviating the esophageal cancer bur-
den in China. Although we expect for improved thera-
peutic modalities for esophageal cancer, perhaps the
greatest potential lies in the ability to prevent the devel-
opment of esophageal cancer, including the widespread
HPV vaccination. Despite esophageal cancer could be
caused by different factors, we can totally prevent HPV-
related esophageal cancer through vaccine. In addition,
some studies have suggested that patients with HPV-
positive cancers had a better prognosis than patients with
HPV-negative cancers, such as head and neck cancer
[30-33]. Esophagus can be infected with HPV in the same
way as head and neck cancer. It is thus considered that
esophagus might have a similar association and clinical
characteristics. As the first step, our results have demon-
strated the strong association between HPV 16 and
esophageal cancer. Another step is to investigate the
prognostic value of the HPV 16 status in patients with
esophageal cancer in Chinese population. Studies have
reported that the patients with HPV-associated carcin-
oma have an improved prognosis than those with HPV-
negative tumors, such as head and neck cancer [34,35].
Consistent with these results, Cao et al. have demon-
strated that HPV-associated esophageal cancer treated
with surgery achieves a superior outcome compared with
HPV-negative esophageal cancer [36]. However, there
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HPV infection in esophageal cancer may be a factor indi-
cating a relatively poor prognosis [37,38]. The relation-
ship between the immune system, HPV status, and
outcome of esophageal cancer is an interesting research
area. Such research will have significant implication for
esophageal cancer treatment.
This meta-analysis shows minimal heterogeneity or
publication bias, and that no single study affects the
summary effect significantly. The pooled result is further
validated by the stratified analysis. All these strengthen
the finding of the association between HPV 16 and
esophageal cancer. However, there are still some limita-
tions that should be addressed. First of all, due to lack of
detailed information on confounders such as age, gender,
smoking, assumption of alcohol, which were also risk
factors of esophageal cancer, we could not adjust for
these confounders which may affect the association
between HPV 16 and esophageal cancer. Further studies
should focus on this issue and provide more information
on type-specific HPV risk on esophageal cancer. Sec-
ondly, we cannot exclude the effect of contamination of
samples in this study which can directly affect the detec-
tion of HPV 16. Roden et al. reported that dehydrated
HPV could maintain 100% infectivity for one day [39].
Ferenczy et al. and Strauss et al. found that HPV DNA
existed on fomites and various medical surfaces [40,41],
which should be responsible for sample contamination
[39]. Despite our efforts to control the impact of con-
tamination, this was difficult as many studies did not
report on these issues. Future studies on the association
between HPV and esophageal cancer should avoid con-
tamination and record the quality control measures,
which will help us to understand the role of HPV in
esophageal cancer. Thirdly, we mainly focused on the
association between HPV 16 and esophageal cancer in
this study and did not investigate the overall HPV risk
on esophageal cancer which is essential for esophageal
cancer prevention in China. We will conduct further
research to obtain more information.Conclusions
This study indicates that HPV-16 infection may be a risk
factor for esophageal cancer among Chinese population,
supporting an etiological role of HPV16 in this malig-
nancy. We believe that this is a major step forward for
this controversial issue and our results may have signifi-
cant implications for esophageal cancer prevention in
China. Further studies are needed to elucidate the role
of HPV in esophagus carcinogenesis with careful consid-
eration of study design and laboratory detection method,
providing more accurate assessment of type specific
HPV risk on esophageal cancer.Competing interests
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